Teva Pharmaceutical R&D Day 2026: First-in-Class Drugs for Tourette Syndrome, Celiac Disease, and IBD Scarring
Tech Times
Teva Pharmaceuticals announced three first-in-class drug candidates targeting previously untreatable aspects of Tourette syndrome, celiac disease, and inflammatory bowel disease scarring, marking a shift toward innovation for the company. Ecopipam, a selective D1/D5 dopamine receptor antagonist for Tourette syndrome, demonstrated significant tic reduction in clinical trials and received FDA Priority Review and Orphan Drug Designation. These developments highlight Teva's transformation into a biopharmaceutical innovator with a robust pipeline of novel therapies.
All articles from 12 November 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.
Get this news by email
Daily or as a weekly roundup in your inbox. You confirm your address first; every email has an unsubscribe link. For another topic or language, use the subscribe page.